Research & development in support of the US army medical materiel development activity (usammda) for the performance of a phase i, multi-center, randomized, double-blind, placebo-controlled study to…

Ended Awarded Last action

Contract number
0002
Awardee
Awarding agency
Obligated
$24,245,008

Award facts

Opportunity
Contract value 100% obligated
$24,245,007.50 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
Pricing
Cost Plus Fixed Fee
Place of performance
Australia
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action 22 · Tafenoquine clinical trials $6,087
Funding Only Action 21 · R & d - ophthalmic safety of TQ VS placebo -$229,989
Supplemental Agreement for work within scope 20 · Per section 711 of the 2019 ndaa, usamraa transferred to DHA 10/1/2022, DE-OB funds, and adjust award amount. -$3,299
Supplemental Agreement for work within scope 19 $0
Supplemental Agreement for work within scope 18 · This award provides for clinical trials that will assess the long term ophthalmic safety of tafenoquine (TQ) after 12 months of exposure. -$61,445
Funding Only Action 17 · Incremental funding for clin 0001 r & d - ophthalmic safety of TQ VS placebo $867,071
Funding Only Action 16 · Incremental funding. $1,270,754
Supplemental Agreement for work within scope 15 · Modification to extend period of performance, increase cost and add clause 52.204-25. $0
Funding Only Action 14 · Modification for incremental funding for r & d - ophthalmic safety of TQ VS placebo. $2,156,497
Funding Only Action 13 · Modification to DE-obligate excess funding from clin 0001 for the eye study intended to evaluate the long term safety of an antimalarial prophylactic for DOD… -$1,847,168
Funding Only Action 12 · The purpose of this MOD is to modify the DVC contract W81XWH-15-d-0037-0002 to provide incremental funding on clin 0001 for the eye study intended to evaluate… $4,595,062
Supplemental Agreement for work within scope 11 · R & d - ophthalmic safety of TQ VS placebo. MOD to add the requirement for a c-ssrs suicide ideation assessment to the PWS and remove costs associated with… -$54,228
Funding Only Action 10 · Modification to add incremental funding in support of a phase i, multi-center, randomized, double-blind, placebo-controlled study to assess the long-term… $2,344,297
Supplemental Agreement for work within scope 9 · Modification to add two (2) trial sites for performance of a phase i, multi-center, randomized, double-blind, placebo-controlled study to assess the long-term… $0
Funding Only Action 8 · Incremental funding $2,553,413
Funding Only Action 7 $2,000,000
Funding Only Action 6 $2,000,000
Other Administrative Action 5 $1,219,871
Funding Only Action 4 $2,442,914
Funding Only Action 3 $500,000
Other Administrative Action 2 $2,000,000
Other Administrative Action 1 $485,171
Original award $2,000,000
Show all 23

About this award

Written by GovTribe AI ·

The U.S. Defense Health Agency awarded Dynport Vaccine Company LLC a $24.2 million cost-plus-fixed-fee delivery order on March 22, 2017, to conduct research and development in support of the U.S. Army Medical Materiel Development Activity. The contract funds a Phase I, multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate the long-term ophthalmic safety of tafenoquine compared to placebo. The work is being performed in Australia and is scheduled for completion by July 31, 2022. This delivery order is issued under the Medical Product Research and Development IDIQ contract vehicle, which provides a framework for clinical trial services and biopharmaceutical product development support.

Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, brings extensive experience in infectious disease therapeutics and clinical trial execution to this engagement. The contractor has a demonstrated track record of supporting government agencies including the National Institutes of Health, Department of Health and Human Services, and the Department of Defense through preclinical development, clinical trials, and regulatory support services. No set-aside designation was applied to this award, which represents a continuation of Dynport's role as a key provider of clinical trial infrastructure and vaccine development support across the federal health and defense sectors.

Description

As the agency reported it.

Research & development in support of the US army medical materiel development activity (usammda) for the performance of a phase i, multi-center, randomized, double-blind, placebo-controlled study to assess the long-term ophthalmic safety of tafenoquine versus placebo.

Quick answers

Who was awarded contract 0002?

0002 was awarded to Dynport Vaccine Company LLC by Defense Health Agency (Department of Defense) on March 22, 2017.

How much is contract 0002 worth?

The government has obligated $24,245,008 on 0002.

Is contract 0002 an order under another contract?

Yes. 0002 is a delivery order under W81XWH15D0037, an indefinite delivery contract, on Medical Product Research and Development.

Was contract 0002 competed?

The extent of competition for 0002 was full and open competition. The government received 2 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login